Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1L1 | Q9UHC9 | 7/20 | 0.61 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.61 |
| ▸ | CRYAB | P02511 | 1/20 | 0.61 |
| ▸ | HMGCR | P04035 | 1/20 | 0.61 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.61 |
| ▸ | ITGAV | P06756 | 1/20 | 0.61 |
| ▸ | OSBP | P22059 | 1/20 | 0.61 |
| ▸ | RORC | P51449 | 1/20 | 0.61 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.61 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.61 |
| ▸ | GRIN1 | Q05586 | 7/20 | 0.55 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.55 |
| ▸ | GRIN2A | Q12879 | 6/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31504640 | 0.89 | PTPN1 (0.59) | NPC1L1NR1H3SRD5A1 | |
| SCHEMBL25333524 | 0.87 | NPC1L1 (0.70) | NPC1L1NR1H3CRYABHMGCRITGB3 | |
| SCHEMBL25333525 | 0.87 | NPC1L1 (0.70) | NPC1L1NR1H3CRYABHMGCRITGB3 | |
| SCHEMBL7753172 | 0.83 | NR1H3 (0.78) | NPC1L1NR1H3CRYABHMGCRITGB3 | |
| SCHEMBL10784914 | 0.83 | NR1H3 (0.78) | NPC1L1NR1H3CRYABHMGCRITGB3 | |
| SCHEMBL8561190 | 0.83 | NR1H3 (0.78) | NPC1L1NR1H3CRYABHMGCRITGB3 | |
| SCHEMBL8561197 | 0.83 | NR1H3 (0.78) | NPC1L1NR1H3CRYABHMGCRITGB3 | |
| SCHEMBL23312299 | 0.83 | NR1H3 (0.78) | NPC1L1NR1H3CRYABHMGCRITGB3 | |
| SCHEMBL11650951 | 0.83 | NR1H3 (0.78) | NPC1L1NR1H3CRYABHMGCRITGB3 | |
| SCHEMBL8636407 | 0.83 | NR1H3 (0.78) | NPC1L1NR1H3CRYABHMGCRITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154193-A1 | STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Cholesgen (Shanghai) Co., Ltd. (CN) | 2025-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250154193-A1 | STEROID COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SREBF1, SREBF2, CYP46A1 | NPC1L1 62/4885NR1H3 5/4885CRYAB 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.